Dopamine receptor plasticity following MPTP-induced nigrostriatal lesions in the mouse

F B Weihmuller; J P Bruno; N H Neff; M Hadjiconstantinou

doi:10.1016/0014-2999(90)90324-y

Dopamine receptor plasticity following MPTP-induced nigrostriatal lesions in the mouse

Eur J Pharmacol. 1990 May 16;180(2-3):369-72. doi: 10.1016/0014-2999(90)90324-y.

Authors

F B Weihmuller¹, J P Bruno, N H Neff, M Hadjiconstantinou

Affiliation

¹ Department of Psychology, College of Social and Behavioral Studies, Ohio State University, Columbus 43210.

PMID: 2365010
DOI: 10.1016/0014-2999(90)90324-y

Abstract

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) destroys dopamine-containing nigrostriatal neurons and increases the apparent Bmax of both D1 and D2 binding sites in the striatum. However, the changes of Bmax occur at different intervals after the lesion. Up-regulation of D2 sites becomes evident about 3 weeks after the lesion and lasts for about 3 months. In contrast, about 3 months are required for the up-regulation of D1 sites and increased binding is still evident after 5 months.

MeSH terms

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / analogs & derivatives*
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
3,4-Dihydroxyphenylacetic Acid / metabolism
Animals
Corpus Striatum / drug effects
Corpus Striatum / metabolism*
Dopamine / metabolism
In Vitro Techniques
Kinetics
Male
Mice
Receptors, Dopamine / drug effects*
Spiperone / metabolism
Substantia Nigra / drug effects
Substantia Nigra / metabolism*
Up-Regulation / drug effects

Substances

Receptors, Dopamine
3,4-Dihydroxyphenylacetic Acid
1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine
Spiperone
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Dopamine